Evotec SE (BIT:1EVT)

Market Cap	835.01M -42.9%
Revenue (ttm)	756.33M -2.7%
Net Income	-158.98M
EPS	-0.90
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,534
Average Volume	1,702
Open	4.919
Previous Close	5.314
Day's Range	4.447 - 4.919
52-Week Range	4.447 - 8.386
Beta	n/a
RSI	27.68
Earnings Date	Apr 8, 2026

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 4,788
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1EVT

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.